{"id":"commercial-formulation-etanercept","safety":{"commonSideEffects":[{"rate":"37","effect":"Injection site reactions"},{"rate":"29","effect":"Upper respiratory tract infections"},{"rate":"12","effect":"Headache"},{"rate":"7","effect":"Dizziness"},{"rate":"1-2","effect":"Serious infections"},{"rate":"<1","effect":"Tuberculosis reactivation"}]},"_chembl":null,"_fixedAt":"2026-03-30T11:59:51.540746","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept consists of the extracellular ligand-binding portion of the human TNF receptor II fused to the Fc region of human IgG1. It acts as a soluble TNF receptor that competitively inhibits TNF-α and TNF-β from binding to cell surface TNF receptors, thereby suppressing TNF-mediated inflammatory responses. This mechanism reduces the activation of immune cells and production of inflammatory mediators in autoimmune and inflammatory conditions.","oneSentence":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:26.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Plaque psoriasis"},{"name":"Crohn's disease"}]},"_fixedFields":["modality→Biologic"],"trialDetails":[{"nctId":"NCT02986139","phase":"PHASE3","title":"Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-11-29","conditions":"Arthritis, Rheumatoid; Arthritis, Psoriatic","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enbrel"],"phase":"phase_3","status":"active","brandName":"Commercial Formulation Etanercept","genericName":"Commercial Formulation Etanercept","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}